3.2100 -0.02 (-0.62%)
After hours: 4:35PM EST
|Bid||3.2100 x 3000|
|Ask||3.2500 x 2900|
|Day's Range||3.1900 - 3.3900|
|52 Week Range||2.5500 - 7.2500|
|Beta (5Y Monthly)||2.99|
|PE Ratio (TTM)||5.62|
|Earnings Date||Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.30|
Ziopharm Oncology, Inc. (ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to Ziopharm before deducting underwriting discounts and commissions and estimated offering expenses payable by Ziopharm, are expected to be approximately $90.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
Ziopharm Oncology, Inc. (ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
Ziopharm Oncology, Inc. (ZIOP), today announced two publications in peer-reviewed scientific journals supporting the Company’s ongoing clinical programs by reinforcing two of the foundational technologies underlying the Company’s approach to the genetic modification of T cells to target cancer. A paper in the journal Blood enhances the clinical data set surrounding the Sleeping Beauty platform by indicating encouraging long-term survival of patients that received CAR-T. The Clinical Cancer Research publication demonstrates that T-cell receptors (TCRs) targeting genetic changes within TP53 can be obtained from T cells in the peripheral blood, overcoming the need to harvest a patient’s tumor. The Company plans to expand its existing library of TCRs as part of its commitment to advance clinical development for the treatment of patients whose solid tumors have driver mutations, including in TP53, using Sleeping Beauty-modified T cells.
BOSTON, Dec. 19, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.
Is ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019. The options were granted as an inducement material to such employee’s entering into employment with Ziopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $4.59 per share, the closing price of the Company’s common stock on November 21, 2019.
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced the presentation of pre-clinical data of Rapid Personalized Manufacture (RPM), in the “Adoptive Immunotherapy: Mechanisms and New Approaches” session at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando. “These pre-clinical data demonstrate that T cells genetically modified using DNA plasmids from the Sleeping Beauty system to express TCR with membrane bound IL-15 (mbIL15) exhibit anti-tumor effects,” said Drew Deniger, Ph.D., leader of Ziopharm’s TCR program.
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults, at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix.
BOSTON, Nov. 18, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November.
BOSTON, Nov. 11, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.
– Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD.
BOSTON, Oct. 30, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm’s Sleeping Beauty immunotherapy program to use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors (TCRs) in T cells (referred to as TCR-T). “We are delighted to deepen our relationship with MD Anderson, which provides treatment to a large and diverse population of cancer patients with solid tumors,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.
Ziopharm Oncology (ZIOP) recently announced that the FDA has cleared an investigational new drug application (IND) for a Phase I trial to test their 3rd generation CD19-specific CAR-T, explains biotech sector specialist John McCamant, editor of The Medical Technology Stock Letter.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that Chris Bowden, M.D., an oncology drug development executive with more than 20 years leadership experience spanning pre-clinical development through commercialization, including the approval of several cancer medicines, has been appointed to the Company’s Board of Directors. Dr. Bowden is the Chief Medical Officer of Agios Pharmaceuticals and was previously Vice President, Product Development Oncology, at Genentech, Inc., a member of the Roche Group. “We are delighted to welcome Dr. Bowden to the Ziopharm Board.
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application (IND) for a phase 1 clinical trial to evaluate CD19-specific CAR-T, produced using a process termed rapid personalized manufacture (RPM), as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The IND clearance builds upon the Company’s experience with two prior generations of immunotherapy trials using the Sleeping Beauty platform, which it believes is the most clinically-advanced non-viral approach to the genetic modification of T cells.
By David Bautz, PhD TSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Business Update Updated Data from Phase 2b Trial Presented at Targeting Innate Immunity Congress On September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin,
BOSTON, Aug. 28, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a.